| Literature DB >> 34993191 |
Soonkyu Hwang1,2, Yongjae Lee1,2, Ji Hun Kim1,2, Gahyeon Kim1,2, Hyeseong Kim1,2, Woori Kim1,2, Suhyung Cho1,2, Bernhard O Palsson3,4,5, Byung-Kwan Cho1,2,6.
Abstract
Heterologous production of recombinant proteins is gaining increasing interest in biotechnology with respect to productivity, scalability, and wide applicability. The members of genus Streptomyces have been proposed as remarkable hosts for heterologous production due to their versatile nature of expressing various secondary metabolite biosynthetic gene clusters and secretory enzymes. However, there are several issues that limit their use, including low yield, difficulty in genetic manipulation, and their complex cellular features. In this review, we summarize rational engineering approaches to optimizing the heterologous production of secondary metabolites and recombinant proteins in Streptomyces species in terms of genetic tool development and chassis construction. Further perspectives on the development of optimal Streptomyces chassis by the design-build-test-learn cycle in systems are suggested, which may increase the availability of secondary metabolites and recombinant proteins.Entities:
Keywords: chassis; heterologous expression; recombinant protein; secondary metabolite; streptomyces
Year: 2021 PMID: 34993191 PMCID: PMC8724576 DOI: 10.3389/fbioe.2021.804295
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Rational engineering strategies for heterologous production of secondary metabolites and recombinant proteins in Streptomyces.
Selected examples of strategies for cloning and assembly of secondary metabolite BGCs.
| Strategies | Principle | NP (class, size (kb)) | Heterologous host | Advantage | Limitation | Reference |
|---|---|---|---|---|---|---|
| Genomic library | • Restriction digestion and ligation | A54145 (NRPS, 60) |
| • Suitable for small to large size of fragments | • Efficiency of ligation and transformation is low | ( |
| • Integrative into chromosome with prophage cassette | Kinamycin (PKS, >63) |
| ||||
| Abyssomicin (PK, 74) |
| • Genome sequence data is not required | • Screening colonies could be time consuming and laborious process | |||
| Spinosad (PK, 80) |
| |||||
|
| ||||||
| FK506 (PKS, 120) |
| |||||
| pSBAC | • Restriction digestion and ligation | Pikromycin (PKS, 60) |
| • ∼200 kb gDNA fragments could be inserted into shuttle vector with high efficiency | • Challenging to achieve unique restriction sites | ( |
|
| ||||||
| • Homologous recombination and ligation | Tautomycetin (PKS, 80) |
| • Fragments must be free of such restriction sites | |||
|
| ||||||
| Meridamycin (PKS, 95) |
| |||||
| LCHR, LLHR | • Recαβ-mediated linear to circular homologous recombination | Gougerotin (other, 17.6) |
| • Rapid (2–3 days) and do not rely on PCR amplification | • Difficult to clone large size of DNA fragments | ( |
| • RecET-mediated linear to linear homologous recombination | Streptoketides (PKS, 21.7) |
| ||||
| Oxytetracycline (PK, 29) |
| • Suitable for small size of DNA fragments | ||||
| ExoCET | • | Salinomycin (PKS,106) |
| • Application of a wide range of fragment size and genome complexities | • Efficiency is not so high |
|
| TAR | • | Enterocin (PK, 21) |
| • Suitable for cloning various size of DNA fragments | • Some clones are unstable in yeast, so undergo deletions during mitotic propagation in yeast cells | ( |
|
| ||||||
| Grecocycline (PKS, 36) |
| |||||
| Mithramycin A (PK, 45) |
| • Highly efficient recombination system | ||||
| Taromycin A (NRPS, 67) |
| |||||
| DNA assembler | • PCR-amplified small DNA fragments and vectors are co-transformed into | PTMs (PKS/NRPS, 18) |
| • Refactoring for cryptic gene clusters in a single-step manner with high efficiency | • Difficult to clone large size of DNA fragment | ( |
| Aureothin (PK, 29) |
| |||||
| Spectinabilin (PK, 45) |
| |||||
| Gibson assembly | • Two adjacent DNA fragments with same terminal sequences overlap to become one fragment by 5′ exonuclease, DNA polymerase and DNA ligase | Bicyclomycin (other, 9) |
| • Assembled DNA molecules up to 100 kb in | • Inefficiency for large size of DNA fragments | ( |
| Kocurin (RiPP, 12) |
| • Not rely on restriction enzyme site | ||||
| Conglobatin (NRP, 41) |
| |||||
| DiPAC | • Long amplicon PCR and | Hapalosin (PK/NRP, 23) |
| • Simultaneous cloning and refactoring of BGCs are possible | • Time-consuming for cloning and costly cloning reagents | ( |
| Anabaenopeptin NZ857 (NRP, 29) |
| |||||
| Erythromycin (PK, 54.6) |
| |||||
| CATCH | • RNA-guided Cas9 nuclease excision and Gibson assembly | Septacidin (other, 24) |
| • Various size of any DNA fragments can be extracted and assembled in a single step | • Efficiency is not so high | ( |
| Tü3010 (PK/NRP, 27.4) |
|
Examples of genetic parts for gene expression.
| Vector | Strategies | Name | Reference |
|---|---|---|---|
|
| Low-copy | pRM5, pHU204, pOJ446, pIJ101 | ( |
| High-copy | pUC119, pKC1139 |
| |
|
| ΦC31 | pSET152, pOJ436, pIJ6902, pIJ10702 (cosmid), pHL931 (BAC), pESAC13 (BAC), pCAP01 (TAR cloning) | ( |
| ΦBT1 | pMS82, pJ10257, pSBAC | ( | |
| VWB | pCLY10 (TAR cloning) |
| |
|
|
|
| |
| Integrase | ΦC31 | Derived from |
|
| ΦBT1 | Derived from | ( | |
| VWB | Derived from bacteriophage VWB, introduced to a tRNAArg (AGG) gene in several |
| |
| RP3 | Derived from |
| |
| R4 | Derived from |
| |
| TG1 | Derived from |
| |
| Bxb1 | Derived from Mycobacteriophage Bxb1 |
| |
| SV1 | Derived from |
| |
| Φ1/6 | Derived from prophage Φμ1/6, introduced to chromosome of tetracycline producing strains, |
| |
| ΦOZJ | Derived from actinophage OzzyJ |
| |
| ΦJoe |
|
| |
| Constitutive Promoter |
| Derived from |
|
|
| Trinucleotide deletion in the |
| |
| SF14 | Derived from phage 119 isolated from |
| |
|
| Derived from |
| |
|
| Derived from |
| |
|
| Derived from |
| |
|
| Engineered by removing the binding sites of ScbR and ScbR2 regulators, then by using random mutation |
| |
|
| Derived from |
| |
| Synthetic promoter library | Randomized to construct synthetic promoter library in |
| |
| Randomized synthetic promoter library in |
| ||
| Synthetic promoter library based on |
| ||
| Inducible promoter |
| Thiostrepton inducible promoter from |
|
|
| Tetracycline inducible promoter |
| |
|
| Isovaleronitrile or ε-caprolactam inducible promoter from |
| |
|
| Xylose inducible promoter |
| |
|
| Oxytetracycline inducible promoter |
| |
| PA3 | Resorcinol inducible promoter |
| |
| P21- | Cumate inducible promoter |
| |
| Terminator | TD1 | Derived from |
|
| Fd | Derived from |
| |
|
| Heterologous expression level of glucuronidase in Mycobacteria |
| |
| Riboswitch | Synthetic theophylline-dependent riboswitches |
| |
Examples of Streptomyces heterologous expression chassis.
| Chassis | Genetic manipulation | Natural product | Product type | Effect | Reference |
|---|---|---|---|---|---|
|
| • Deletion of four endogenous BGCs (Act, Red, Cpk, and CDA) from the genome of | Chloramphenicol, congocidine, cypemycin, grisemycin, actagardine, planosporicin, GE37468, napsamycin, clorobiocin, coumermycin A1, caprazamycin, FK506/FK520 (tacrolimus), merochlorins, gougerotin, endophenazine, roseoflavin, holomycin, and tunicamycin | NRP, PK, linaridin, RiPP, oligopyrrole, aminocoumarin, and other | • Reduced competition for precursor | ( |
| • High conjugation frequency | |||||
|
| • Introduction of point mutations in | • Higher transcriptional and translational fidelity | |||
| • Clean metabolic background | |||||
|
| • Introduction of point mutations in | • Induction of global upregulation of SM biosynthesis | |||
| • Production of chloramphenicol and congocidine 40-, and 30-fold than | |||||
|
| • Deletion of all three Type III PKS genes ( | Flaviolin | PK | • Specialized expression host for actinobacterial type III PKS genes |
|
|
| • Deletion of all the 10 PKS and NRPS BGCs and a 900 kb subtelomeric sequences from the genome of | Galbonolide B | PK | • Reduced competition for precursor | ( |
|
| • Deletion of Act, Red, and CDA BGCs from | Murayaquinone, hybrubins, and Whole genome BAC library from | PK and PKS-NRPS hybrid | • Positive regulation of |
|
| • Introduction of the global regulatory genes ( | |||||
|
| • Stepwise integration of two global regulatory genes ( | Murayaquinone, hybrubins, dehydrorabelomycin, piericidin A1, and actinomycin D | PK, PKS-NRPS hybrid, and NRP | • Superior host for high-throughput heterologous expression of BGCs and LEXAS screening |
|
| • 74 times higher yields of murayaquinone than that of SBT5 | |||||
|
| • Deletion of negative regulatory gene ( | • Increased heterologous production of PKs, NRPs, and hybrid antibiotics | |||
| • Introduction of global regulatory gene ( | • Positive morphological change | ||||
| • The yields of murayaquinone were 96 times higher than that of SBT5 (10.6 mg/L) | |||||
|
| • Deletion of 9 endogenous BGCs (178.5 kb) within the chromosome of |
| Library | • Increased success rate in isolation of novel bioactive NPs originating from eDNA |
|
| • Introduction of two additional phage phiC31 | |||||
|
| • Deletion of 11 endogenous BGCs (228.5 kb) | Tunicamycins, deoxycoformycin, deoxycinnamycin, and 7 new compounds | Nucleoside antibiotic, lanthipeptide, and aromatic polyketide | • Used in the production of amino acid-based natural products | |
| • Introduction of two additional phage phiC31 | |||||
|
| • Deletion of 15 endogenous BGCs using IMES from | Cinnamycin, tunicamycin, didesmethylmensacarcin, fralnimycin, bhimamycin A, aloesaponarin II, albucidin, cittilinsn, and | PK, RiPP, and new compound | • Clean metabolic background |
|
| • The activation of the cryptic BGCs from | |||||
|
| • Introduction of two additional phage phiC31 | Tunicamycin B2, moenomycin M, didesmethyl mensacarcin, demethoxyaranciamycinone, griseorhodin, and cinnamycin | PK, saccharide, and lantipeptide peptide | • Reduced competition for precursor | |
| • Multi-copy integration | |||||
|
| • Introduction of a three-gene cassette for the biosynthesis of ethylmalonyl-CoA and salinomycin | Actinorhodin | PK | • Host for heterologous production of PK |
|
| • Subsequent deletion of the salinomycin BGC | • Rich supplies of common PK precursors including malonyl-CoA, methylmalonyl-CoA, and ethylmalonyl-CoA | ||||
| • Enhanced intracellular energy (ATP) and reducing power (NADPH/NADP+) | |||||
|
| • Deletion of 1.51 Mb left arm (two majors endogenous BGCs) and oligomycin BGC from | Pladienolide | PK | • Clean metabolic background |
|
| • Increase in genetic stability | |||||
| • Reduced competition for precursor | |||||
| • Large amount of cell mass | |||||
| • Functionalization of positive regulator gene | |||||
| • Capable of expressing diverse BGCs | |||||
|
| • Deletion of three terpene compound BGCs (geosmin, neopentalenolactone, and carotenoid) from | Cephamycin, and amorpha-1,11-diene | NRP and plant terpenoid intermediate | • Acyl-CoA precursor pool supply | |
| • Production of unnatural metabolites by combinatorial biosynthesis | |||||
| • PKS production at the industrial level | |||||
|
| • Isogenic to SUKA17, the right side of the deletion region of SUKA17 was replaced by a mutant-type | Shinorine, porphyra-334, 17-hydroxycyslabdan A, raimonol, pholipomycin, resistomycin, bafilomycin B1, and nemadectin | NRP, PK, terpene, and other | • Positive morphological change | ( |
|
| • Deletion of 0.7 Mb non-essential genomic region (7 putative BGCs and complete natamycin BGC) | eGFP, indigoidine, and actinorhodin | NRP and PK | • Enhanced ATP and reducing power |
|
| • Improved productivity of protein and secondary metabolite | |||||
| • Positive morphological change | |||||
| • Clean metabolic background | |||||
| • Increase in genetic stability | |||||
| • Promising platform cell to produce PK | |||||
|
| • Deletion of all | Gentamicin A2, kanamycin | Aminoglycoside antibiotics | • Used in the production of polyketides and aminoglycosides |
|
|
| • Deletion of both | Doxorubicin | PK | • Used in the sugar engineering |
|
|
| • Deletion of | Tylosin polyketide synthase, epothilones, flavonoid, stilbene, flavones, flavonols, barbamide, naringenin, pinocembrin, and 4-O-demethylbarbamide | PKS, plant-specific PK and lipopeptide (hybrid NRPS-PKS) | • Diverse precursors for PKs | ( |
| • Used in the production of PKS, NRPS, and PKS-NRPS hybrid | |||||
|
| • Deletion of jadomycin biosynthetic gene cluster | Oxytetracycline | PK | • Normal growth, differentiation | ( |
| • Downstream of Pik PKS ( | • Cleaner metabolite profiles | ||||
| • Improved oxytetracycline production up to 430 mg/L in 48 h | |||||
|
| • Deletion of whole oxytetracycline gene cluster of | Chlortetracycline | PK | • Several grams level of titer with industrial grade, one of the highest titer reports of heterologous antibiotics production |
|
| • Introduction of constitutively expressed cluster-situated activator gene |
Selected examples of optimization of heterologous protein production in Streptomyces since 2010.
| Optimization | Product | Native host | Expression host | Plasmid | Promoter | Promoter host | Signal peptide | Signal peptide host | Host engineering | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Gene expression | DagA (agarase) |
|
| pWHM3-TR1R2 |
|
| Native |
| ||
| pHSEV-1 |
|
| Native | |||||||
| pUWL201 PW |
|
| Native | |||||||
| SCO3487 (β-agarase) |
|
| pUWL201 PW |
|
| Native |
| |||
| PVA (penicillin V acylase) |
|
| pEM4 |
|
| Native |
| |||
| BTA hydrolase |
|
| pIJ8600 |
|
| Native |
| |||
| Transglutaminase |
|
| pIJ86 | Native | Native |
| ||||
| Native (negative regulatory element deletion) | Native | |||||||||
| Native; codon-optimized | ||||||||||
| Lipase | Metagenomic |
| pIAFC109 | C109p | - | Native |
| |||
| Cel6A (endoglucanase) |
|
| pZRJ362 | Xylose isomerase promoter |
| Native |
| |||
| Phospholipase D |
|
| pIJ12739 |
|
| Native |
| |||
| Chitosanase |
|
| pHM8aBΔM | Native | Native |
| ||||
| Native (negative regulatory element deletion) | Native | |||||||||
|
| Native | |||||||||
| Native | Native |
| ||||||||
| Native (negative regulatory element deletion) | Native | |||||||||
|
| Native | |||||||||
| pFDES | Native | Native | ||||||||
| Native (negative regulatory element deletion) | Native |
| ||||||||
| Chitinase | Metagenomic |
| pIJ86 |
|
| Native |
| |||
|
| ||||||||||
|
| ||||||||||
| Glutenase |
|
| pIJ86 |
|
| Native |
| |||
| Chitobiase |
|
| pIJ350 |
|
| Native |
| |||
| Sfp2 (keratinase) |
|
| pJTU4881 | Xylose isomerase promtoer |
| Native |
| |||
| O-glycoprotein |
|
| pIJ6021 |
|
| Native |
| |||
| Secretion system | DagA (agarase) |
|
| pIJ486 | Native | Native |
| |||
| Native | Native |
| ||||||||
| DagA (agarase) |
|
| pAGAs1 | Native | Native | WT |
| |||
|
| ||||||||||
|
| ||||||||||
|
|
| WT | ||||||||
|
| ||||||||||
|
| ||||||||||
| Both | Transglutaminase |
|
| pTONA4 |
|
|
|
|
|
|
| Pernisine |
|
| pVF |
| Synthetic |
|
|
|
| |
| Native | ||||||||||
| Native; codon-optimized | ||||||||||
| Xys1 (xylanase) |
|
| pN702GEM3 | Native | Native |
| ||||
|
| ||||||||||
| α-amylase |
| |||||||||
| α-amylase + 3 codons of the mature amylase | ||||||||||
|
|
| Native | ||||||||
|
|
| Native | ||||||||
|
|
| Native | ||||||||
|
|
| Native | ||||||||
|
|
| Native | ||||||||
| α-amylase |
|
|
| Native | ||||||
|
| ||||||||||
|
|
| Native | ||||||||
| Small laccase |
| pHJL401 | xysA |
| Native | |||||
|
| ||||||||||
|
| ||||||||||
| XylE (catechol 2,3-dioxygenase) |
|
| pAB04 |
|
| Native |
| |||
|
|
| Native | ||||||||
|
| Synthetic | Native | ||||||||
| pVF |
|
| Native | |||||||
|
|
| Native | ||||||||
|
| Synthetic | Native | ||||||||
| pVM |
|
|
|
| - | |||||
|
|
| - | ||||||||
|
|
| - | ||||||||
|
|
| - | ||||||||
|
|
| - | ||||||||
|
|
| - | ||||||||
|
|
| - | ||||||||
|
|
| - | ||||||||
| AppA (phytase) |
| pVM |
|
|
|
| - | |||
|
|
| - | ||||||||
|
|
| - | ||||||||
| pVF |
|
|
|
| - | |||||
|
| Synthetic | - | ||||||||
| pAB04 |
|
|
|
| - | |||||
| CelA (cellulase A) |
|
| pIJ486 |
|
|
|
| - |
| |
| hTNF-α | human |
| pIJ486 |
|
|
|
| - |
| |
|
| ||||||||||
| Interleukin-6 | human |
| pIMB1 |
|
|
|
| - |
| |
|
|
| - | ||||||||
|
|
| - | ||||||||
| Transglutaminase |
|
| pIJ702 |
|
|
|
| - |
| |
| β-1,4-endoglucanase |
| - | ||||||||
| β-glucosidase | - | |||||||||
| Transglutaminase |
|
| pIJ86 | Native | Native |
| ||||
| Native | Native (TTA codon to CTG codon) | |||||||||
|
|
| Native (TTA codon to CTG codon) | ||||||||
|
| Native | Native (TTA codon to CTG codon) | ||||||||
|
| Native | Native (TTA codon to CTG codon) | ||||||||
| Aminopeptidase |
|
| Transglutaminase promoter |
| Transglutaminase (TTA codon to CTG codon) |
| - | |||
|
| - | |||||||||
|
| - | |||||||||
|
| - | |||||||||
| Phenylalanine ammonia-lyase |
|
| Transglutaminase promoter |
| Transglutaminase (TTA codon to CTG codon) |
| - | |||
|
| - | |||||||||
|
| - | |||||||||
|
| - | |||||||||
| Streptokinase |
|
| pWHM3-TR1R2 |
|
|
|
| - |
| |
| Native | ||||||||||
| pUWL201PW |
|
| Native | |||||||
| pSEV1 |
|
| Native | |||||||
| Streptavidin |
|
| pTONA4 |
|
|
|
| - |
| |
| Native | ||||||||||
FIGURE 2High-throughput DBTL cycle of rational engineering for heterologous production using specialized Streptomyces chassis library.